Neurological Symptoms in Palliative Care Patients

Johanna Anneser1*, Victoria Arenz1 and Gian Domenico Borasio2

1 Palliative Care Team, Department of Psychosomatic Medicine and Psychotherapy, Klinikum rechts der Isar, Technical University Munich, Munich, Germany, 2 Service de Soins palliatifs et de support, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, Switzerland

Background: Neurological expertise in palliative care may be required not only for patients with primary neurological disorders but also for patients with non-neurological diseases suffering from burdensome neurological symptoms. The aim of this study was to determine the prevalence of neurological diagnoses and symptoms in palliative care patients, as well as the related burden and impact on everyday life.

Methods: We analyzed retrospectively the medical records of 255 consecutive patients from a tertiary medical center, at the time point of referral to an inpatient palliative care consultation service. In addition, 100 patients prospectively answered a questionnaire which included the assessment of neurological symptoms, as well as numeric rating scales for quality of life, symptom-specific burden, and restrictions in everyday life.

Results: Forty-one patients (16%) suffered from a primary neurological disease. Most decisions regarding the termination of life-sustaining measures concerned this group (20/22, 91%). Neurological symptoms (excluding pain) were documented in 122 patients (48%) with an underlying non-neurological disease. In the questionnaire study, 98/100 patients reported at least one neurological or neuropsychiatric symptom, most frequently sleeping problems (N = 63), difficulty concentrating (N = 55), and sensory symptoms (N = 50). Vertigo/dizziness (N = 19) had the greatest impact on everyday life (7.57/10 ± 2.17) and the highest symptom-specific burden (7.14 ± 2.51). Difficulty concentrating (restrictions in everyday life/burden) and pain intensity were the only symptoms significantly correlated with quality of life (r = −0.36, p = 0.009/r = −0.32; p = 0.04; r = −0.327, p = 0.003).

Conclusion: Neurological diseases and symptoms are frequent among palliative care patients and are often associated with a high symptom burden, which may severely affect the patients’ lives. It is thus of paramount importance to implement neurological expertise in palliative care.

Keywords: palliative care, neurological symptoms, prevalence, symptom burden, quality of life

INTRODUCTION

Palliative care aims to provide physical, psychosocial, and spiritual care for terminally ill patients and their families. Although differences between countries exist, palliative care has been linked traditionally to oncological diseases and internal medicine/oncology specialists still constitute the largest part of the palliative care workforce in many countries (e.g., Germany, USA, Japan, and...
Canada) (1–4), while neurologists constitute less than 3% of physicians that are certified in palliative care (1, 2, 4). On the other hand, neurological and neurosurgical diseases have been found to be the second most common conditions in patients seen by a palliative care inpatient consultation service (5) and the most common diagnostic group in patients with non-malignant diseases (6).

Several reviews advocate a better integration of palliative care in the overall care of patients with neurological diseases (7–9). Both neurological and palliative care expertise are required, e.g., for patients with intracranial processes in order to assess prognosis, to substantiate decisions on the withholding or withdrawal of life-sustaining measures and to help the family understand the nature of an imminent persistent vegetative state or brain death. Although care concepts for people with motor neuron diseases may be an encouraging example of the successful integration of palliative care and neurology, many patients with neurodegenerative, neuro-oncological as well as neurovascular diseases still have a wide range of unmet palliative care needs (9, 10).

In addition, neurological expertise is required for non-neurological palliative care patients suffering from neurological symptoms. Scarce data are available on the prevalence of neurological symptoms in a general palliative care population and most of the data have been assessed retrospectively. In a meta-analysis looking at symptom prevalence in a total of 25,000 patients with incurable cancer (11), "neurological symptoms" (without further specification) were documented in 15% of all patients and in 34% within their last 2 weeks of life. Even less is known about the relevance of neurological symptoms for the patients’ lives (e.g., their subjective burden, the impact on patients’ quality of life [QoL], or possible restrictions in the patients’ everyday lives). We therefore combined a review of patient charts with a prospective questionnaire study in order to gain an overview of the frequency of neurological symptoms as well as their clinical relevance in a general palliative care population.

MATERIALS AND METHODS

Retrospective Chart Analysis
The charts of 255 consecutive patients who had been referred to the palliative care inpatient consultation service, were analyzed. Data were collected over a period of 9 months. Demographic data, diagnosis, reasons for current admission to the hospital, previous treatments as well as neurological and neuropsychiatric symptoms and preconditions—as listed in the patient charts prior to the referral to the palliative care team—were assessed.

Prospective Questionnaire Study
A total of 100 consecutive inpatients, referred to the palliative care inpatient consultation service, who were willing to participate and able to give their written informed consent were included in the questionnaire study. The questionnaire was administered in the form of a structured interview. The specific symptom burden is the degree to which the patients’ everyday lives were compromised by a symptom and the patients’ overall QoL were assessed using 0–10 point numeric rating scales (NRSs). NRS is a validated measure for QoL and is considered to assess the patient’s general QoL rather than only its health-related aspects (12).

In order to differentiate lightheadedness or pre-syncopal syndromes from vertigo/dizziness, we asked the patients for the sensation of spinning/swaying and/or unsteady gait.

Actual pain intensity was assessed using a visual analog scale (VAS). To be able to compare the symptom “pain” with other neurological/neuropsychiatric symptoms, we assessed also the symptom-specific burden and restrictions in everyday life due to pain. Neuropathic pain was diagnosed by clinical assessment of the pain characteristics and the association with typical symptoms in the same area (e.g., tingling, numbness).

The “Confusion Assessment Method” (CAM) questionnaire was used when delirium was suspected. The CAM is a validated instrument for the diagnosis of delirium in a variety of medical settings (13, 14).

The Patient Health Questionnaire (PHQ-4) was used to screen patients for anxiety and depression.

In addition, patients were asked to name the symptoms, which were currently most distressing to them (max. 5). All patients who agreed received a structured neurological examination. Diagnostic workup of burdensome neurological symptoms was offered if indicated (e.g., neuro-otologic tests in patients with vertigo/dizziness). In addition, all patients were offered psychological support if desired. Descriptive statistics was performed using SPSS 24 (IBM, Chicago, IL, USA). Correlation analysis (Spearman’s rho) was performed. The study was carried out in accordance with the recommendations of the Ethics Committee of the Technical University Munich. The protocol was approved by the Ethics Committee of the Technical University Munich (No: 5682/13). All subjects gave written informed consent in accordance with the Declaration of Helsinki.

RESULTS

Analysis of Patient Charts
Reasons for Admission to the Hospital as Documented in the Patient Chart
Patients from nine different departments had been referred to the palliative care inpatient consultation service. For patient characteristics, see Table 1. In 84 out of 255 patients (33%), the main reasons or one of the main reasons for admission to the hospital were neurological symptoms (other than pain). 28 patients (11%) had been admitted directly to the departments of neurology or neurosurgery. The presence of neurological symptoms and preconditions—as documented in the admission examination or discovered in other examinations during the hospital stay—was assessed. Patients were assigned to one of four groups. (10 patients remained unclassified due to incomplete data or unclear assignment):
TABLE 1 | Analysis of patients’ medical records: patients’ characteristics and neurological symptoms.

| Patient characteristics | 255 patients |
|-------------------------|--------------|
| Gender | 118 (45%) female |
| Mean age | 67 ± 13 years |
| Mean duration of disease | 36 ± 54 months |
| Cancer diagnosis | 217 (85%) |
| Primary brain tumor or cerebral metastases | 49 (19%) |
| Previous surgery | 138 (65%) |
| Previous chemotherapy | 157 (63%) |
| Previous radiotherapy | 100 (40%) |

Neurological symptoms as documented in the patient chart

| Symptoms | Group 1: 25/41 (61%) Group 2: 12/99 (12%) Group 3: 4/23 (17%) |
|----------|---------------------------------------------------------------|
| Central paresis | 41 (16%) |
| Seizures | 27 (11%) |
| Dementia | 14 (6%) |
| Confusion | 47 (19%) |
| Other CNS symptoms | 66 (26%) |
| Peripheral paresis | 27 (11%) |
| Sensory symptoms | 23 (9%) |

Group 1: primary neurological condition, group 2: neurological symptoms presumably caused by a non-neurological underlying disease, and group 3: neurological symptoms presumably independent from the underlying disease.

Termination of Life-Sustaining Measures
After palliative care consultation, life-sustaining measures had been terminated in 22 patients, and 20 (91%) of them had been classified in group I (neurological condition as primary disease).

Patient Questionnaire Study
Patient Characteristics
For the questionnaire study, 100 of 255 consecutive patients who were willing to participate and able to give their informed consent were included (50% female; 98 patients with cancer, 13 of them with brain metastases). 73 of 255 were not able to give their informed consent, 39 patients declined to participate, 32 patients could not be approached before the involvement of the palliative care consultation service, 11 lacked sufficient knowledge of the German language. None of the 41 neurologic patients could be recruited (20 were unconscious, 15 patients—mostly severe stroke or advanced glioblastoma—were conscious, but unable to consent, 5 refused to participate, and 1 lacked sufficient knowledge of the German language). 98 patients reported at least one neurological or neuropsychiatric symptom excluding pain, 38 patients stated that a neurologist or psychiatrist had treated them before admission to the hospital. Clinical neurological examination was performed after the patient interviews and objectified the symptoms reported (e.g., extent and degree of paresis or paresthesia). The values for “restrictions in everyday life” and “burden due to a specific symptom” were correlated, except for taste abnormalities.

Prevalence of Neurological Symptoms
The prevalence of neurological/neuropsychiatric symptoms, the symptom-specific burden, and restrictions in everyday life in patients participating in the questionnaire study is shown in Table 2. Sleeping problems (63/100), difficulties concentrating (55/100), and sensory symptoms (50/100) occurred most frequently. In addition, several neurological/neuropsychiatric symptoms were ranked among the most burdensome overall symptoms (Table 3).

Neurological Symptoms and QoL
The mean QoL (±SD) (NRS 0–10) of all patients was 3.7 (±2.3). The only neurological non-pain symptom significantly correlated to QoL was difficulty concentrating (restrictions in everyday life: \( r = -0.36, p = 0.009 \); symptom-specific burden: \( r = -0.32; p = 0.04 \)). In addition, the sum scores (restrictions in everyday life and symptom-specific burden) comprising the three most frequent neurological/neuropsychological symptoms (sleeping problems, difficulty concentrating and sensory symptoms) were significantly correlated with QoL (\( r = -0.348, p = 0.0004; r = -0.322, p = 0.001 \)).

Pain
52 patients reported having only one pain localization, 27 patients reported having two, and 5 reported having three pain localizations. The most frequent type of pain was predominantly nociceptive (45 patients), followed by mixed pain (29 patients), and predominantly neuropathic pain (10 patients). Actual pain intensity—as measured by a VAS—correlated significantly with...
QoL \( (r = -0.327, p = 0.003) \). Restrictions in everyday life and subjective burden due to pain did not correlate significantly with patients’ QoL \( (r = -0.135, p = 0.21; r = -0.07, p = 0.517) \).

### Depression and Anxiety (PHQ-4)

Normal scores (0–2) were found in 28 patients, mild distress (3–5) in 28 patients, moderate (6–8) in 23, and severe distress (9–12) in 21 patients. PHQ-4 showed a moderate correlation with QoL \( (r = 0.271, p = 0.007) \). The PHQ-4 depression subscore was significantly correlated with the neuropsychological symptom “difficulty concentrating” \( (r = 0.361, p = 0.003) \) and moderately, but significantly correlated with QoL \( (r = -0.271, p = 0.007) \).

### DISCUSSION

Several studies investigated the presence of burdensome symptoms in patients with advanced cancer and palliative care patients [for a review, see Ref. (11, 15)]. Isolated neurological symptoms such as agitation/delirium or vertigo/dizziness have been assessed in this context. However, a systematic and detailed analysis of neurological symptoms in palliative care patients has not been carried out before. We found that almost half of the palliative care patients without a primary neurological disease had neurological symptoms documented in their charts, and 98% of patients in the prospective study reported at least one burdensome neurological/neuropsychological symptom. This is considerably higher than previously described (11). These findings have an immediate clinical relevance in that significant suffering arises from symptoms, which are underdiagnosed and therefore insufficiently treated. Our data suggest that this may be the case for a variety of neurological symptoms, which come with a high subjective burden and/or restrictions in everyday life, e.g., vertigo/dizziness, coordination difficulties, or double vision (Table 2).

### Sensory Symptoms

The prevalence of sensory symptoms (numbness, tingling, and burning) reported in patients with advanced cancer and in palliative care patients varies widely from 6 to 36% (16–19). These variations may be caused by the different characteristics of the populations investigated, but also by the differing assessment methods used. Not surprisingly, it has been found that the prevalence of many symptoms is considerably lower when assessed using medical records as compared with studies using questionnaires or structured interviews (11). Correspondingly, the prevalence of sensory symptoms in our questionnaire study (50%) was markedly higher than the results from the chart reviews (9%).

### Dysgeusia

Similar results were obtained for the prevalence of “taste abnormalities” (dysgeusia) in palliative care patients: in our study, the occurrence of dysgeusia in the patients’ charts was 0%, while 32% of patients in the questionnaire study reported taste abnormalities (20), while dysgeusia was documented in only 1–2% of patients’ charts (17, 18).

### Dizziness/Vertigo

Interestingly, our questionnaire study revealed “dizziness/vertigo” as the most burdensome symptom with the greatest impact on everyday life. “Vertigo”—defined as an erroneous sense of motion
and unsteadiness—is a relatively common condition, which also occurs in the general population: a survey in Germany reported a 12-month prevalence of 22.9% (21), while the point prevalence in palliative care patients with cancer was 10% (18). “Dizziness” is a term mostly used in a wider sense, which includes symptoms that range from a vague feeling of unsteadiness to severe vertigo. Pooled prevalence of dizziness in patients with incurable cancer was 17% in a previous study (11) and is similar to the occurrence found in our study (19%). Our questionnaire allowed only an initial screening for dizziness/vertigo without providing an accurate diagnosis. A detailed analysis of dizziness/vertigo in palliative care patients is urgently warranted, since effective treatment is available for many forms of this symptom (22).

**Pain**

Pain had a prevalence of 84% in our palliative care population with a high symptom-specific burden and relevance for everyday life. Actual pain intensity correlated significantly with QoL, while symptom-related burden and restrictions in everyday life due to pain did not. An association between pain and QoL has been described previously, using the “brief pain inventory” (23, 24), but also an NRS (25). In contrast to the VAS assessing actual pain intensity, our items asking for a “symptom-specific burden” or “restrictions in everyday life” implicate significant elements of personal judgment and/or coping and may therefore provide different results when correlated with QoL. 39% of our—predominantly oncologic—patients suffered from neuropathic pain. This matches the prevalence of neuropathic pain in cancer patients assessed in palliative care (43%) and hospice settings (35%) (26). A recent review revealed that neuropathic pain in cancer patients is often insufficiently treated because of “incorrect use of co-analgesics” (27).

**Delirium**

In 47 (19%) patient charts from our cohort, “confusion” was documented. This percentage matches previous observations in a palliative care population (28). Since patients had to give informed consent to participate in the prospective study, only 12 patients underwent CAM testing in the context of our study, which was positive in 11 patients. Prevalence, diagnosis, treatment, and prognosis of confusion/delirium in palliative care patients have been widely studied (29). Recently, a randomized controlled trial showed that palliative care patients treated with standard neuroleptic medication had more delirium-specific symptoms, more side effects and a shorter survival rate than placebo-treated patients (30). This underscores the necessity of a careful diagnostic evaluation and individualized management of delirium in palliative care. Expertise in neuropsychopharmacology and in the early detection of extra-pyramidal side effects of neuroleptic medication may be helpful to tailor treatment for these patients.

**Anxiety and Depression**

Anxiety and depression are common symptoms in palliative care patients (31) with an estimated prevalence ranging between 7 and 49% (32). Correspondingly, 21% of our patients scored 9–12/12 in the PHQ, indicating severe psychological distress.

**Sleeping Problems**

Similar to previous studies (33–35), sleeping problems were a frequent complaint among palliative care patients with a relatively high symptom-specific burden and impact on everyday activities. Sleep problems are multifactorial in many patients, although the moderate correlation with subjective burden due to pain suggests that inappropriate pain therapy may contribute to sleep disturbances in our patient population.

**Cognitive Symptoms**

A frequent occurrence of mild-to-moderate self-reported cognitive symptoms, such as difficulty concentrating or memory disturbances, has been described previously in palliative care and cancer patients (16, 17). In addition, in a previous study, cancer outpatients named “difficulty concentrating” as one of the 13 top-ranked symptoms (36). Correspondingly, difficulty concentrating was the only symptom (except pain) significantly correlated with QoL in our study. A previous report showed that complaints of difficulty concentrating did not correlate with objective measurements of cognitive function in palliative care patients (37). In our study group “difficulty concentrating” correlated significantly with the PHQ-4 depression subscore. It has been shown previously that the prevalence of depression in palliative care patients and patients with advanced cancer is greater than in the general population (38). Since difficulty concentrating is a complaint which is frequently associated with depression (39), this symptom may be part of a coexisting depressive syndrome. However, cognitive impairment and difficulty concentrating may also be accompanying symptoms of CNS processes or side effects of radiation therapy [for review, see Ref. (40)]. Expertise in organic forms of cognitive impairment may be helpful for the diagnostic classification of these symptoms in order to initiate appropriate treatment.

**Neurological/Neuropsychological Symptoms and QoL**

The significant correlations between the sum scores of the three most frequently reported neurological/neuropsychiatric symptoms (sleeping problems, difficulty concentrating, and sensory symptoms) and QoL, as well as the frequency at which neurological problems are reported to be one of the most distressing overall symptoms (Table 3), underscore the extent to which these symptoms may compromise the patients' well-being. Many neurological symptoms that turned out to be burdensome in the questionnaire study had not been assessed prior to the referral to the palliative care team. This underlines previous findings that physicians frequently tend to focus on their specialized scope of practice rather than giving sufficient attention to burdensome (e.g., neurological) symptoms in severely ill patients (41).

**Patients With Primary Neurological Diagnoses**

The percentage of patients with a primary neurological diagnosis (16%) in our retrospective cohort is higher than the proportions found in previous studies (9.2 and 8.8%) (5, 6); one of which however excluded patients with primary brain conditions.
tumors (5). In our study, the overwhelming majority (91%) of decisions regarding termination of life-sustaining measures (e.g., terminal extubation, termination of artificial hydration, and nutrition) were taken in patients with primary neurological diseases. This is in line with the findings of Liu et al. (6), who showed that “eliciting goals of care” was the most frequent reason for palliative care consultations among neurological patients. In-depth knowledge of the course and prognosis of neurological diseases is indispensable when discussing treatment options with the patients’ families. Generally, there is an increasing awareness that many patients suffering from neurological diseases have palliative care needs (7, 8) and efforts have been made to improve the education of neurologists in this context (42).

Neurological Expertise in Palliative Care

Given the high prevalence and the considerable burden of neurological symptoms in palliative care patients, as well as the relatively high percentage of patients with primary neurological disorders, it becomes evident that neurological expertise is crucial in palliative care. It can be fostered by increased neurological training in postgraduate palliative care education, as well as by recruiting neurologists in specialized palliative care centers. However, relatively few neurologists choose to abandon their primary specialty to concentrate on palliative medicine full-time. Clinical rotations of neurologists in palliative care teams may not only help to integrate neurological knowledge into palliative care, but also open up career options for young neurologists (2).

Limitations

The single center design may limit the generalizability of the study. However, referral of patients from nine different departments of our university hospital resulted in a highly heterogeneous study population with a wide range of diagnoses. Our study was conducted in a tertiary medical center that has departments of neurology and neurosurgery. Therefore, the number of patients with primary neurological disorders may be higher than in less specialized hospitals. In the prospective cohort, 98% of patients suffered from cancer. The significance of the results from the questionnaire study may therefore apply primarily to oncological palliative care patients. Unfortunately, this also reflects the disproportionate prevalence of tumor patients in most specialized palliative care centers worldwide.

REFERENCES

1. German Society for Palliative Care. Member Structure (in German) (2011). Available from: http://www.dgpalliativmedizin.de/images/intern/mitgliederschaft/Mitgliederstruktur_der_DGP_Mai_2011.pdf (Accessed: June 30, 2017).
2. Dallara A, Tolchin DW. Emerging subspecialties in neurology: palliative care. Neurology (2014) 82:640–2. doi:10.1212/WNL.0000000000000121.
3. Morita T, Oyama Y, Cheng SY, Suh SY, Koh SJ, Kim HS, et al. Palliative care physicians’ attitudes toward patient autonomy and a good death in east Asian countries. J Pain Symptom Manage (2015) 50(2):190–9.e1. doi:10.1016/j.jpainsymman.2015.02.020
4. Canadian Society of Palliative Care Physicians Human Resources Committee. National Palliative Medicine Survey Data Report (2015). Available from: https://www.cma.ca/Assets/assets-library/document/en/advocacy/pm-survey-data-report-may2015-e.pdf (Accessed: February 6, 2018).
5. Chahine LM, Malik B, Davis M. Palliative care needs of patients with neurologic or neurosurgical conditions. Eur J Neurol (2008) 15:1265–72. doi:10.1111/j.1468-1331.2008.02319.x
6. Liu Y, Kline D, Aerts S, Youngwerth JM, Kutner JS, Silau S, et al. Inpatient palliative care for neurological disorders: lessons from a large retrospective series. J Palliat Med (2017) 20:59–64. doi:10.1089/jpm.2016.0240
7. Borasio GD. The role of palliative care in patients with neurological diseases. Nature Rev Neurol (2013) 9:292–5. doi:10.1038/nrneurol.2013.49
8. Boersma I, Miyasaki J, Kutner J, Kluger B. Palliative care and neurology. Time for a paradigm shift. Neurology (2014) 83:561–7. doi:10.1212/WNL.0000000000005674

9. Provinciali L, Carlini G, Tarquini D, Defanti CA, Veronese S, Pucci E. Need for palliative care for neurological diseases. Neuro Sci (2016) 37: 1581–7. doi:10.1007/s10072-016-2614-x

10. Robinson MT, Holloway RG. Palliative care in neurology. Mayo Clin Proc (2017) 92(10):1592–601. doi:10.1016/j.mayocp.2017.08.003

11. Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A. Symptom prevalence in patients with incurable cancer. A systematic review. J Pain Symptom Manage (2007) 34:94–104. doi:10.1016/j.jpainsymman.2006.10.015

12. Chiò A, Gauthier A, Montuschi A, Calvo A, Di Vito N, Ghiglione P, et al. A cross sectional study on determinants of quality of life in ALS. J Neurol Neurosurg Psychiatry (2004) 75(11):1597–601. doi:10.1136/jnnp.2003.033100

13. Inouye S, van Dyck C, Alessi C, Balkin S, Siegal A, Horwitz R. Clarifying confusion: the confusion assessment method. Ann Intern Med (1990) 113(12):941–8. doi:10.2162/0003-4819-113-12-941

14. Shi Q, Warren L, Saposnik G, Macdermid JC. Confusion assessment methodology: a systematic review of published literature and results from a survey conducted in 50 palliative care inpatients. J Pain Symptom Manage (2015) 47(1):190–10. doi:10.1016/j.jpainsymman.2013.02.016

15. Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Coyle N, et al. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res (1994) 3:183–9. doi:10.1007/BF00345383

16. Shiq W, Warren L, Saposnik G, Macdermid JC. Confusion assessment method: a systematic review and meta-analysis of diagnostic accuracy. Neuropsychiatr Dis Treat (2013) 9:359–70. doi:10.2147/NDT.S49520

17. Potter J, Hami F, Bryan T, Quigley C. Symptoms in 400 patients referred to a specialist palliative medicine service: a retrospective review. J Pain Symptom Manage (2003) 24:895–900. doi:10.1016/S1091-2415(03)00060-7

18. Srömgren AS, Groenvold M, Pedersen L, Olsen AK, Sjogren P. Symptomatology of cancer patients in palliative care: status quo or opportunities for improvement? Palliat Med (2007) 20:40–6. doi:10.1177/0269216307079067

19. Walker J, Holm Hansen C, Martin P, Sawhney A, Thakkkurvarah P, Beale C, et al. Prevalence of depression in adults with cancer: a systematic review. Ann Oncol (2013) 24:895–900. doi:10.1093/annonc/mds575

20. Amr A, Lawlor PG, Quinn S, Draper B, Caplan GA, Rowett D, et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Intern Med (2017) 177:34–42. doi:10.1001/jamainternmed.2016.7491

21. Neumann SC, de Graeff A, Voest EE, de Haes JC. Are anxiety and depression mood related to physical symptom burden? A study in hospitalized advanced cancer patients. Palliat Med (2007) 21:541–6. doi:10.1177/0269216307079067

22. Anneser et al. Neurological Symptoms in Palliative Care Patients. Palliat Support Care (2010) 8:133–6. doi:10.1007/s10072-009-00067-4

23. Leonard MM, Agar M, Spiller JA, Davis B, Mohamad MM, Meagher DJ, et al. Delirium diagnostic and classification challenges in palliative care: subsyndromal delirium, comorbid delirium-dementia, and psychosis subtypes. J Pain Symptom Manage (2014) 48:199–214. doi:10.1016/j.jpainsymman.2014.03.012

24. Agar MR, Lawlor PG, Quinn S, Draper B, Caplan GA, Rowett D, et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Intern Med (2017) 177:34–42. doi:10.1001/jamainternmed.2016.7491

25. Neumann SC, de Graeff A, Voest EE, de Haes JC. Are anxiety and depression mood related to physical symptom burden? A study in hospitalized advanced cancer patients. Palliat Med (2007) 21:541–6. doi:10.1177/0269216307079067

26. Walker J, Holm Hansen C, Martin P, Sawhney A, Thakkkurvarah P, Beale C, et al. Prevalence of depression in adults with cancer: a systematic review. Ann Oncol (2013) 24:895–900. doi:10.1093/annonc/mds575

27. Conill C, Verger E, Henriques I, Saiz N, Espier M, Lugo F, et al. Symptom prevalence in the last week of life. J Pain Symptom Manage (1997) 14:328–31. doi:10.1016/S0885-3924(97)00263-7

28. Mercadante S, Aielli F, Adile C, Ferrara P, Valè E, Cartoni C, et al. Sleep disturbances in patients with advanced cancer in different palliative care settings. J Pain Symptom Manage (2015) 50:768–92. doi:10.1016/j.jpainsymman.2015.06.018

29. Mercadante S, Adile C, Ferrara P, Masedu F, Valenti M, Aielli F. Sleep disturbances in advanced cancer patients admitted to a supportive/palliative care unit. Support Care Cancer (2017) 25:1301–6. doi:10.1007/s00520-016-3524-4

30. Williams AR, Mowlazadeh B, Sisler L, Williams PD. Self-reported assessment of symptoms and self-care within a cohort of U.S. veterans during outpatient care for cancer. Clin J Oncol Nurs (2015) 19:595–602. doi:10.1188/15.CJON.595-602

31. Klempärd P, Hilton P, Moen J, Foungner B, Borghcrevink PC, Kaasa S. Self-reports are not related to objective assessments of cognitive function and sedation in patients with cancer pain admitted to a palliative care unit. Palliat Med (2002) 16:513–9. doi:10.1191/0269216302pm587oa

32. Mitchell AJ, Chan M, Bhatti H, Haltom M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol (2011) 12(12):160–74. doi:10.1016/S1470-2045(11)70002-X

33. Papakosta GI, Culpepper L. Understanding and managing cognition in the depressed patient. J Clin Psychiatry (2015) 76(4):418–25. doi:10.4088/JCP.13086ah1c

34. Armstrong CL, Gyato K, Awadalla AW, Porch B, Grattan-Jackson E, Sargeant-Jackson R, et al. Palliative care provision for patients with chronic non-cancer related pain. J Pain Symptom Manage (2010) 39:399–402. doi:10.1016/j.jpainsymman.2009.11.003

35. Bainsbridge D, Seow H, Sussman J, Pond G, Martelli-Reid L, Herbert C, et al. Multidisciplinary health care professionals’ perceptions of the use and utility of a symptom assessment system for oncology patients. J Oncol Pract (2011) 7(1):19–23. doi:10.1200/JOP.2010.000015

36. The Lancet Neurology. Integrating palliative care into neurological practice. Editorial. Lancet Neurol (2017) 16:489. doi:10.1016/S1474-4422(17)30176-X

37. Wallace EM, Tierman E. Referral patterns of nonmalignant patients to an Irish specialist palliative medicine service: a retrospective review. Am J Hosp Palliat Care (2013) 30(4):399–402. doi:10.1177/1081962612453080

38. Johannes AM. Palliative care provision for patients with chronic obstructive pulmonary disease. Health Qual Life Outcomes (2007) 5:17. doi:10.1186/1477-7525-5-17

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.